此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Altering Mechanisms of Frailty in Persons Living With HIV Aged 50 to 65 (ALTER)

2021年8月3日 更新者:Jennifer Klinedinst、University of Maryland, Baltimore

People living with HIV are living longer as their disease is controlled with antiretroviral medications. Yet they are experiencing frailty more often and more than ten years earlier than those without HIV. In elderly persons without HIV, frailty is associated with decreased muscle strength and chronic inflammation. Less is known about what is driving early frailty in HIV or effective prevention measures for aging adults with HIV.

It may be that having HIV infection impairs energy production by mitochondria within the cells and contributes to the muscle weakness and inflammation accompanying frailty in people living with HIV . This study will examine the impact of six weeks of moderately paced walking on energy production in the cells, inflammation markers and frailty scores in people living with well-controlled HIV who are aged 50 to 65.

研究概览

地位

撤销

干预/治疗

研究类型

介入性

阶段

  • 不适用

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

50年 至 65年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Adults aged 50 to 65
  • Documentation of HIV infection from Medical Provider
  • Currently receiving antiretrovirals
  • HIV viral load less than 50 iu/mL for at least six months
  • CD4 count at least 350 cell/mm3 for the last six months
  • Willing and able to walk at least 30 minutes 3 times weekly within 30 minutes of UMB
  • Speaks English

Exclusion Criteria:

  • Current smokers
  • Weight less than 110 pounds
  • Subjects taking long-term corticosteroids equivalent to 10mg/day or more, or immunomodulators
  • Subjects with conditions known to affect inflammatory or mitochondrial function other than HIV, such as rheumatoid arthritis, gout, heart failure, chronic obstructive pulmonary disease, chronic kidney disease, diabetes, Parkinson's disease, Alzheimer's disease, active hepatitis, sleep apnea or autoimmune diseases.
  • Current drug or alcohol use or dependence or unstable mental health conditions that, in the opinion of the investigator, would interfere with adherence to study requirements

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:预防
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
其他:People living with HIV
Subjects will act as own control between Visit one and Visit two, then will complete six weeks of walking, 30 minutes per walk, three times weekly between Visit Two and Visit Three.
Moderately paced walking of approximately 100 steps/minute for 30 minutes three times weekly for six weeks.
其他名称:
  • 体力活动

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Mitochondrial Respiration PBMC and platelets
大体时间:Day 0, Week 6, Week 12 with intervention between weeks 6 and 12
Change in mitochondrial respiratory capacity after a six-week walking intervention
Day 0, Week 6, Week 12 with intervention between weeks 6 and 12

次要结果测量

结果测量
措施说明
大体时间
Inflammation IL-1β
大体时间:Day 0, Week 6, Week 12 with intervention between weeks 6 and 12 months
Change in IL-1β after a six-week walking intervention
Day 0, Week 6, Week 12 with intervention between weeks 6 and 12 months
Inflammation IL-6
大体时间:Day 0, Week 6, Week 12 with intervention between weeks 6 and 12
Change in IL-6 after a six-week walking intervention
Day 0, Week 6, Week 12 with intervention between weeks 6 and 12
Inflammation IL-10
大体时间:Day 0, Week 6, Week 12 with intervention between weeks 6 and 12
Change in IL-10 after a six-week walking intervention
Day 0, Week 6, Week 12 with intervention between weeks 6 and 12
Inflammation TNF-α
大体时间:Day 0, Week 6, Week 12 with intervention between weeks 6 and 12
Change in TNF-α after a six-week walking intervention
Day 0, Week 6, Week 12 with intervention between weeks 6 and 12
Inflammation hsCRP
大体时间:Day 0, Week 6, Week 12 with intervention between weeks 6 and 12
Change in hsCRP after a six-week walking intervention
Day 0, Week 6, Week 12 with intervention between weeks 6 and 12

其他结果措施

结果测量
措施说明
大体时间
Frailty Related Phenotype
大体时间:Day 0, Week 6, Week 12 with intervention between weeks 6 and 12
Change in frailty phenotype score (0-5 with 3 to 5 indicating frailty) after a six-week walking intervention
Day 0, Week 6, Week 12 with intervention between weeks 6 and 12

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Jennifer Klinedinst, PhD、Associate professor

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2020年5月30日

初级完成 (实际的)

2020年5月30日

研究完成 (实际的)

2020年5月30日

研究注册日期

首次提交

2020年3月19日

首先提交符合 QC 标准的

2020年3月24日

首次发布 (实际的)

2020年3月25日

研究记录更新

最后更新发布 (实际的)

2021年8月11日

上次提交的符合 QC 标准的更新

2021年8月3日

最后验证

2021年8月1日

更多信息

与本研究相关的术语

其他相关的 MeSH 术语

其他研究编号

  • HP-00089501

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅